• Responsible for the overarching global CDx strategy across projects in targeted therapeutic areas• Lead the development and implementation of diagnostic strategies for individual projects and/or therapeutic areas• Direct the development, outsourcing and validation of clinically applicable companion diagnostic assays for FIH and registrational studies• Design, implement and oversee diagnostic testing and data analysis• Provide expertise to development project teams to ensure access to state-of-the-art thinking on appropriate diagnostic technologies, evaluating their scientific basis and clinical applicability, the validation status and any technical or statistical issues related to the proposed companion diagnostic assay• Lead joint development teams between AbbVie and Dx partners to ensure co-development timelines are met• CDx lead for Minimal Residual Disease (MRD) strategy development across programs

Responsible for developing and implementing the overall companion diagnostic strategy for several therapeutic programs spanning early to late phase clinical development.

- Led the companion diagnostic and translational biomarker efforts for several assets in various stages of clinical development from phase I to phase III to include:• Represent translational medicine and companion diagnostics on study teams, core teams or other cross-functional teams• Responsible for companion diagnostic and translational biomarker sections of clinical protocols, CRFs, CSRs, IBs, lab manuals, regulatory submissions, etc.• Responsible for partner selection, alliance management, budgeting and overall strategy development for CDx portions of development programs• Serve as regulatory lead for all interactions with the FDA regarding CDx development• Regularly interface with external vendors and CROs involved in biomarker services and serve as technical lead in negotiations with and auditing of these partners• Responsible for analysis and interpretation of biomarker data for use in abstract and manuscript submissions

Led strategy development & new product planning for pipeline products in oncology portfolio- Clinical Development Planning- Market Analysis, Competitive Intelligence- New Technology Evaluation and due dilligence- Perform primary and secondary market research to inform new product development - New product concept business case development

- Global pipeline strategy for oncology companion diagnostics and personalized medicine.- Supported corporate BD through the scientific, medical and technical assessment of biomarker in-licensing and acquisition opportunities.- Market entrance strategy & business intelligence.- KOL Management & Strategic Alliances

Grew market presence of quantitative PCR and laboratory developed test (LDT) workflow through partnerships and strategic alliances with key opinion leaders. Led market research to guide product development strategy and identified and developed programs to support expansion into new market areas.

Postdoctoral studies in the department of Pharmacology/University of Colorado Cancer Center with emphasis on kinase regulation and mechanisms of response to DNA damage in molecular oncology under the direction of Dr. James L. Maller.

Postdoctoral studies in the department of Genetics and Tumor Cell Biology with emphasis on the mechanisms of tumor suppression and leukemogenesis under the direction of Dr. Charles J. Sherr and Dr. Martine F. Roussel